AZ's Alexion Acquisition Looks Astute Bit Of Business
Offers $39bn For Rare Disease Drug Pioneer
Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.
You may also be interested in...
The firms' messenger RNA alliance inked back on 2013 is still very much ongoing but AstraZeneca decided to sell its considerable stake in the high-profile biotech to help finance its own pipeline.
Anticipating approval this summer of the first drug for PFIC, Albireo hopes to add Alagille syndrome and biliary atresia to odevixibat labeling. Firm has modeled its commercial plans on the success of other rare disease firms.
While fast-developing news on COVID-19 is grabbing the headlines, oncology will continue to drive growth in 2021.